

- 2 -

COTTEN *et al.*
Appl. No. 09/688,371

remain the same. Support for the amendment to claim 29 can be found throughout the specification and in the claims as originally filed. In particular, support can be found, *inter alia*, in the specification at page 9, line 25 to page 10, line 6 and in original claims 26 to 29. These changes are believed to introduce no new matter, and their entry is respectfully requested.

Summary

It is respectfully believed that this application is now in condition for examination. Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Peter A. Jackman
Attorney for Applicants
Registration No. 45,986

Date: Jan 18, 2001

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

P:\USERS\PJACKMAN\0652\215\1\pto-prelim-amend
SKGF rev 4/27/00 mac

Applicants: Cotten *et al.*
 Due Date: February 12, 2001
 Art Unit: 1646
 Examiner: To Be Assigned
 Application No.: 09/688,371
 Docket: 0652.2150001
 Filed: October 12, 2000
 Atty: EKS/PAJ
 For: Recombinant, Replication Defective CELO Virus and CELO Virus DNA

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. USPTO Transmittal Cover Letter (*in duplicate*);
2. Preliminary Amendment;
3. Information Disclosure Statement (*in duplicate*);
4. Form PTO-1449 (28 pages) listing 85 documents;
5. Document Nos. AL1, AR1, AS1, AT1, AR2, AS2, AT2, AR3, AS3, AT3, AR4, AS4, AT4, AR5, AS5, AT5, AR6, AS6, AT6, AR7, AS7, AT7, AR8, AS8, AT8, AR9, AS9, AT9, AR10, AS10, AT10, AR11, AS11, AT11, AR12, AS12, AT12, AR13, AS13, AT13, AR14, AS14, AT14, AR15, AS15, AT15, AR16, AS16, AT16, AR17, AS17, AT17, AR18, AS18, AT18, AR19, AS19, AT19, AR20, AS20, AT20, AR21, AS21, AT21, AR22, AS22, AT22, AR23, AS23, AT23, AR24, AS24, AT24, AR25, AS25, AT25, AR26, AS26, AT26, AR27, AS27, AT27, AR28, AS28 and AT28; and
6. One return postcard.

